source
- Gene editor Scribe starts second-half IPO spree with $129M listingA nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 millionEndpoints · 5d ago↗ source
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.Fierce Biotech · 5d ago↗ source
- This Week at FDA: Diamantas touts onshoring efforts, grants for DHTs, and moreWelcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This we…